Accord Healthcare Inc. Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Accord Healthcare Inc. Pharmaceutical Import Records from India — 10 Products, $5.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare Inc. — Pharmaceutical Importer Profile (2026) | 10 Products, $5.0M Trade | TransData Nexus

Accord Healthcare Inc.

Pharmaceutical Importer · Canada · Cardiovascular Focus · $5.0M Total Trade · DGFT Verified

Accord Healthcare Inc. is a pharmaceutical importer based in Canada with a total trade value of $5.0M across 10 products in 6 therapeutic categories. Based on 103 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare Inc. sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare Inc. — Import Portfolio & Supplier Network

Accord Healthcare Inc. import network — 10 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$7.3M	426	100.0%

Accord Healthcare Inc. sources from 1 verified Indian supplier across 248 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharmaceutical drugs and medicine	$364.7K	26
Pharmaceutical drugs and medicine	$200.0K	4
Pharmaceutical drugs and medicine prach-fluoxetine 20 Each hard gelatin capsulecontains fluoxetine hydrochloride ph.	$200.0K	4
Pharma drugs and medicine-ach-apixaban 5MG 180t (ac-can)Each film coated tabletcontains:api qty-6427x1x180t-as per	$125.2K	6
Pharma drugs & medi: fluoxetine	$119.5K	4
Ph.dru.& med.: fluoxetine capsules BP	$102.5K	3
Ph.dru.& med.: paclitaxel injection	$100.0K	2
Ph.dru.& med.: fludarabine phoshate	$100.0K	2
Pharma drugs and medicine-paclitaxel inj300mg/50ML paclitaxel injection USP	$100.0K	2
Pharma drug&med:bendamustine hcl	$85.5K	2
Pharma drugs & medi: mycophenolate	$82.8K	2
Ph.dru.& med.: fluoxetine capsules BP	$81.0K	3
Pharma drugs & medi: ach fluoxetine 20MG	$80.8K	2
Pharma drug&med:bendamustine hcl	$79.4K	2
Pharma drug&med:olmesartan hctz	$73.7K	4

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atorvastatin	Cardiovascular	$2.2M	44	0.1%	4
2	Fluoxetine	CNS & Psychiatric	$800.0K	16	0.1%	2
3	Methotrexate	Immunosuppressants	$535.2K	13	1.5%	14
4	Calcium	Vitamins & Supplements	$350.0K	7	0.0%	5
5	Irinotecan	Oncology	$350.0K	7	0.9%	17
6	Anastrozole	Advanced Oncology	$250.0K	5	0.2%	17
7	Carboplatin	Oncology	$200.0K	4	0.3%	13
8	Cisplatin	Oncology	$148.5K	3	1.2%	15
9	Fludarabine	Advanced Oncology	$100.0K	2	3.5%	4
10	Pemetrexed	Advanced Oncology	$100.0K	2	0.3%	14

Accord Healthcare Inc. imports 10 pharmaceutical products across 6 categories into Canada totaling $5.0M.

Accord Healthcare Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare Inc. is a dynamic pharmaceutical company operating in Canada since 2009, committed to providing high-quality, cost-effective generic medicines to Canadian patients. As a wholly owned subsidiary of Intas Pharmaceuticals, a vertically integrated global pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs), generic medicines, and biopharmaceuticals, Accord Healthcare leverages its parent company's extensive expertise to deliver a diverse portfolio of products.

Headquartered in Kirkland, Quebec, Accord Healthcare focuses on oral solid products, offering more than 45 oral solid and injectable generic molecules. The company's strategic emphasis on oral solids aims to create better value while supporting the needs of wholesaler and retail pharmacy partners. In line with its commitment to patient and medicine safety, Accord has introduced a range of ready-to-use intravenous (IV) oncology products, positioning itself as one of the fastest-growing companies in the Canadian generic sector.

2Distribution Network

Accord Healthcare Inc. operates a centralized distribution model from its headquarters in Kirkland, Quebec, serving the Canadian market. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's strategic focus on oral solid products and ready-to-use IV oncology products suggests a streamlined supply chain designed to efficiently meet the needs of its wholesaler and retail pharmacy partners across Canada. The emphasis on these product categories indicates a distribution network capable of handling both high-volume oral solids and specialized injectable formulations.

3Industry Role

In Canada's pharmaceutical supply chain, Accord Healthcare Inc. functions primarily as a pharmaceutical importer and wholesaler. By sourcing generic medicines from its parent company, Intas Pharmaceuticals, and other suppliers, Accord Healthcare imports finished pharmaceutical formulations into Canada. The company's focus on oral solid and injectable generic medicines positions it as a key player in the wholesale distribution segment, supplying these products to various healthcare providers, including hospitals, clinics, and retail pharmacies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare Inc. demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier: Intas Pharmaceuticals Limited. This single-source dependency indicates a strategic choice to maintain control over product quality and supply chain efficiency. The substantial volume of imports—103 shipments valued at $5.0 million USD—reflects a stable and ongoing relationship between Accord Healthcare and Intas Pharmaceuticals. However, this concentration also exposes Accord Healthcare to potential risks associated with supply chain disruptions, such as production delays or regulatory changes affecting the supplier.

2Supply Chain Resilience

The resilience of Accord Healthcare Inc.'s Indian supply chain is closely tied to its exclusive partnership with Intas Pharmaceuticals Limited. While this relationship ensures consistent product quality and supply, the lack of backup suppliers may pose challenges in the event of disruptions. The importation of 248 unique formulations across six therapeutic categories, including cardiovascular, central nervous system (CNS) and psychiatric, and oncology, indicates a diverse product portfolio. However, the absence of alternative suppliers for these formulations suggests a potential vulnerability to supply chain interruptions. Additionally, the reliance on a single supplier may limit Accord Healthcare's ability to adapt to changes in market demand or regulatory environments.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada, which is responsible for ensuring that all pharmaceutical products meet the necessary safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Food and Drugs Act and the Food and Drug Regulations, which outline the requirements for importing, distributing, and selling pharmaceutical products in Canada. The marketing authorization pathway for Indian generics involves obtaining a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) from Health Canada, demonstrating that the generic product is bioequivalent to the reference product and complies with Canadian standards.

2Import Licensing & GMP

Import licensing requirements in Canada stipulate that all pharmaceutical products must be imported by a company holding a valid Drug Establishment License (DEL) issued by Health Canada. This license ensures that the importer adheres to Good Manufacturing Practices (GMP) and other regulatory requirements. GMP certificate recognition in Canada includes EU GMP, WHO GMP, and PIC/S standards, all of which are accepted by Health Canada. Wholesale distribution authorization requires compliance with the Food and Drug Regulations, including maintaining appropriate storage conditions and record-keeping practices.

Accord Healthcare Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare Inc.'s product category focus on cardiovascular, CNS and psychiatric, and oncology reflects a strategic alignment with prevalent health concerns in Canada. The substantial import value of atorvastatin ($2.2 million) and fluoxetine ($800,000) indicates strong market demand in these therapeutic areas. The inclusion of methotrexate and irinotecan highlights Accord's commitment to providing treatments for complex conditions such as cancer. This product strategy positions Accord Healthcare to address significant health challenges while meeting the needs of healthcare providers and patients.

2Sourcing Profile

Accord Healthcare Inc.'s sourcing strategy emphasizes the importation of generic drugs, particularly oral solids and injectables, from its parent company, Intas Pharmaceuticals Limited. The focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, allows Accord to maintain control over product quality and supply chain efficiency. India's robust pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a strategic partner for Accord Healthcare in fulfilling its product portfolio requirements.

3Market Positioning

Seller's Guide — How to Become a Supplier to Accord Healthcare Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Accord Healthcare Inc., particularly in therapeutic areas where Accord's current sourcing may be limited or where additional suppliers could enhance supply chain resilience. Identifying gaps in Accord's current sourcing, such as specific formulations or dosage forms not currently imported, presents an opportunity for Indian exporters to offer complementary products. Establishing partnerships with Accord Healthcare could facilitate entry into the Canadian market, leveraging Accord's established distribution network and regulatory compliance expertise.

2Requirements & Qualifications

Indian exporters seeking to supply Accord Healthcare Inc. and the Canadian market must ensure that their products comply with Health Canada's regulatory requirements, including obtaining the necessary marketing authorizations. Products must adhere to recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S, and be accompanied by appropriate certifications. Labeling must meet Health Canada's bilingual requirements, and products must undergo batch testing and stability assessments to confirm quality and safety.

How to Approach

Frequently Asked Questions — Accord Healthcare Inc.

What products does Accord Healthcare Inc. import from India?

Accord Healthcare Inc. imports 10 pharmaceutical products across 6 categories. Top imports: Atorvastatin ($2.2M), Fluoxetine ($800.0K), Methotrexate ($535.2K), Calcium ($350.0K), Irinotecan ($350.0K).

Who supplies pharmaceuticals to Accord Healthcare Inc. from India?

Accord Healthcare Inc. sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $7.3M).

What is Accord Healthcare Inc.'s total pharmaceutical import value?

Accord Healthcare Inc.'s total pharmaceutical import value from India is $5.0M, based on 103 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare Inc. focus on?

Accord Healthcare Inc. imports across 6 categories. The largest: Cardiovascular (43.7%), CNS & Psychiatric (15.9%), Oncology (13.9%).

Get Full Accord Healthcare Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.